| Ghiaseddin, Ashley |
EF-41, NCT06556563: /KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma |
|
|
| Recruiting | 3 | 741 | Japan, US | Optune® device, TTFields, Temozolomide, Pembrolizumab, Placebo | NovoCure GmbH, Merck Sharp & Dohme LLC | Glioblastoma | 04/29 | 04/29 | | |
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma |
|
|
| Active, not recruiting | 3 | 305 | Europe, Canada, US | concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group | Brain and Central Nervous System Tumors | 10/25 | 10/25 | | |
2-THE-TOP, NCT03405792: Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma |
|
|
| Active, not recruiting | 2 | 40 | US | Temozolomide (TMZ), Optune System, NovoTTF Therapy, Pembrolizumab, Keytruda | University of Florida, NovoCure Ltd. | Glioblastoma, Glioblastoma, WHO Grade IV | 11/22 | 09/25 | | |
OPTIMUS PRIME, NCT06558214: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial |
|
|
| Recruiting | 2 | 20 | US | Pembrolizumab, Keytruda, Optune GIO®, TTFields, NeuroBlate®, MLA, LITT | University of Florida | Recurrent Glioblastoma | 10/29 | 10/29 | | |
PNOC020, NCT04573140: A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) |
|
|
| Active, not recruiting | 1/2 | 52 | US | Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) | University of Florida, Pacific Pediatric Neuro-Oncology Consortium, University of California, San Francisco, CureSearch, Team Jack Foundation, Florida Department of Health, Food and Drug Administration (FDA) | Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma | 07/29 | 07/30 | | |
RENEW, NCT04963413: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients. |
|
|
| Terminated | 1 | 6 | US | Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF | University of Florida, Immunomic Therapeutics, Inc. | Glioblastoma | 09/23 | 09/23 | | |
ADAGiO, NCT06254326: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients |
|
|
| Active, not recruiting | 1 | 12 | US | TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine | University of Florida, Oligo Nation, Inc | Recurrent Oligodendroglioma, Progressive Oligodendroglioma | 12/27 | 06/28 | | |
NCT06389591: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) |
|
|
| Active, not recruiting | 1 | 24 | US | pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) | University of Florida, National Cancer Institute (NCI) | Recurrent Glioblastoma | 12/27 | 12/28 | | |
IMPACT, NCT05353530: Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma |
|
|
| Recruiting | 1 | 18 | US | Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells, 8R-70CAR T cells | University of Florida, United States Department of Defense, AM Rosen Foundation | Glioblastoma Multiforme, Glioblastoma | 12/27 | 12/42 | | |
| Subramony, Sankarsubramone H |
| No trials found |
